Japan's PMDA Considering Data Monitoring Committee Guidance, Weighs In On Adaptive Design - DIA Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Drug reviewers in Japan do not see as many adaptive trial designs as reviewers in the U.S., and to ensure data integrity for the potentially controversial trials companies should consult with the Pharmaceuticals and Medical Devices Agency as early as possible, an official said, while adding that regulatory guidance may soon be on the way
You may also be interested in...
Convergence Of Clinical Trial Requirements Requires Flexibility Of Industry And Regulators – APEC Harmonization Workshop
Regional harmonization may not be necessary as long as there is regulatory cooperation, says U.S. FDA.
Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
TOKYO - Japan's drug regulator Pharmaceuticals and Medical Devices Agency has opened its doors in the last three years to preapproval discussions with drug companies. While the move has helped somewhat to ease the agency's drug approval lag, it can also pay benefits to companies applying for approvals in neighboring Asian countries
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).